Severity of depression and anxiety are predictors of response to antidepressant treatment in Parkinson's disease

A. J H Moonen, A. Wijers, A. F G Leentjens, C. W. Christine, S. A. Factor, J. Juncos, J. M. Lyness, L. Marsh, M. Panisset, Ronald Pfeiffer, D. Rottenberg, C. Serrano Ramos, L. Shulman, C. Singer, J. Slevin, W. McDonald, P. Auinger, I. H. Richard

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Background: Antidepressants have appeared to be more effective than placebo treatment in treating depressive syndromes in patients with Parkinson's disease (PD). Objective: To identify factors that predict improvement in depressive symptoms during antidepressant treatment in depressed PD patients. Methods: A secondary analysis was performed on the dataset of the Randomized Placebo-controlled Study of Antidepressants in PD (SAD-PD), in which 76 patients received active treatment with either paroxetine or venlafaxine extended release (XR), and 39 patients received placebo treatment. Backward stepwise regression analyses were conducted with change in 24-item Hamilton Depression Rating Scale (HAMD-24) score between assessments at baseline and week 12 as the main outcome measure, and sex, age, baseline HAMD-24 score, Unified Parkinson's Disease Rating Scale section III (UPDRS-III) score, Mini-Mental State Examination (MMSE), and the Clinical Anxiety Scale (CAS) as independent variables. Results: In both the active treatment and placebo groups, higher baseline HAMD-24 score and lower UPDRS-III score were associated with greater reduction in HAMD-24 score. Higher anxiety scores predicted less response in the active treatment group. Higher MMSE scores predicted greater response only in the placebo-treated group. Sex and age were no predictors of response. Conclusions: Higher pre-treatment depression scores and lower pre-treatment anxiety scores are the two most important predictors for improvement during antidepressant treatment in depressed PD patients, which is in line with those found in treatment studies of depressed non-PD patients. Furthermore, our results indicate the requirement for different or more intensive treatment for depressed PD patients with more severe anxiety symptoms.

Original languageEnglish (US)
Pages (from-to)644-646
Number of pages3
JournalParkinsonism and Related Disorders
Volume20
Issue number6
DOIs
StatePublished - 2014
Externally publishedYes

Fingerprint

Antidepressive Agents
Parkinson Disease
Anxiety
Depression
Placebos
Therapeutics
Paroxetine
Depressive Disorder
Regression Analysis
Outcome Assessment (Health Care)

Keywords

  • Clinical trials randomized controlled
  • Depression
  • Parkinson's disease
  • Paroxetine
  • Venlafaxine

ASJC Scopus subject areas

  • Geriatrics and Gerontology
  • Clinical Neurology
  • Neurology
  • Medicine(all)

Cite this

Moonen, A. J. H., Wijers, A., Leentjens, A. F. G., Christine, C. W., Factor, S. A., Juncos, J., ... Richard, I. H. (2014). Severity of depression and anxiety are predictors of response to antidepressant treatment in Parkinson's disease. Parkinsonism and Related Disorders, 20(6), 644-646. https://doi.org/10.1016/j.parkreldis.2014.02.025

Severity of depression and anxiety are predictors of response to antidepressant treatment in Parkinson's disease. / Moonen, A. J H; Wijers, A.; Leentjens, A. F G; Christine, C. W.; Factor, S. A.; Juncos, J.; Lyness, J. M.; Marsh, L.; Panisset, M.; Pfeiffer, Ronald; Rottenberg, D.; Serrano Ramos, C.; Shulman, L.; Singer, C.; Slevin, J.; McDonald, W.; Auinger, P.; Richard, I. H.

In: Parkinsonism and Related Disorders, Vol. 20, No. 6, 2014, p. 644-646.

Research output: Contribution to journalArticle

Moonen, AJH, Wijers, A, Leentjens, AFG, Christine, CW, Factor, SA, Juncos, J, Lyness, JM, Marsh, L, Panisset, M, Pfeiffer, R, Rottenberg, D, Serrano Ramos, C, Shulman, L, Singer, C, Slevin, J, McDonald, W, Auinger, P & Richard, IH 2014, 'Severity of depression and anxiety are predictors of response to antidepressant treatment in Parkinson's disease', Parkinsonism and Related Disorders, vol. 20, no. 6, pp. 644-646. https://doi.org/10.1016/j.parkreldis.2014.02.025
Moonen, A. J H ; Wijers, A. ; Leentjens, A. F G ; Christine, C. W. ; Factor, S. A. ; Juncos, J. ; Lyness, J. M. ; Marsh, L. ; Panisset, M. ; Pfeiffer, Ronald ; Rottenberg, D. ; Serrano Ramos, C. ; Shulman, L. ; Singer, C. ; Slevin, J. ; McDonald, W. ; Auinger, P. ; Richard, I. H. / Severity of depression and anxiety are predictors of response to antidepressant treatment in Parkinson's disease. In: Parkinsonism and Related Disorders. 2014 ; Vol. 20, No. 6. pp. 644-646.
@article{528597b9a4974e05b52cb182587fe262,
title = "Severity of depression and anxiety are predictors of response to antidepressant treatment in Parkinson's disease",
abstract = "Background: Antidepressants have appeared to be more effective than placebo treatment in treating depressive syndromes in patients with Parkinson's disease (PD). Objective: To identify factors that predict improvement in depressive symptoms during antidepressant treatment in depressed PD patients. Methods: A secondary analysis was performed on the dataset of the Randomized Placebo-controlled Study of Antidepressants in PD (SAD-PD), in which 76 patients received active treatment with either paroxetine or venlafaxine extended release (XR), and 39 patients received placebo treatment. Backward stepwise regression analyses were conducted with change in 24-item Hamilton Depression Rating Scale (HAMD-24) score between assessments at baseline and week 12 as the main outcome measure, and sex, age, baseline HAMD-24 score, Unified Parkinson's Disease Rating Scale section III (UPDRS-III) score, Mini-Mental State Examination (MMSE), and the Clinical Anxiety Scale (CAS) as independent variables. Results: In both the active treatment and placebo groups, higher baseline HAMD-24 score and lower UPDRS-III score were associated with greater reduction in HAMD-24 score. Higher anxiety scores predicted less response in the active treatment group. Higher MMSE scores predicted greater response only in the placebo-treated group. Sex and age were no predictors of response. Conclusions: Higher pre-treatment depression scores and lower pre-treatment anxiety scores are the two most important predictors for improvement during antidepressant treatment in depressed PD patients, which is in line with those found in treatment studies of depressed non-PD patients. Furthermore, our results indicate the requirement for different or more intensive treatment for depressed PD patients with more severe anxiety symptoms.",
keywords = "Clinical trials randomized controlled, Depression, Parkinson's disease, Paroxetine, Venlafaxine",
author = "Moonen, {A. J H} and A. Wijers and Leentjens, {A. F G} and Christine, {C. W.} and Factor, {S. A.} and J. Juncos and Lyness, {J. M.} and L. Marsh and M. Panisset and Ronald Pfeiffer and D. Rottenberg and {Serrano Ramos}, C. and L. Shulman and C. Singer and J. Slevin and W. McDonald and P. Auinger and Richard, {I. H.}",
year = "2014",
doi = "10.1016/j.parkreldis.2014.02.025",
language = "English (US)",
volume = "20",
pages = "644--646",
journal = "Parkinsonism and Related Disorders",
issn = "1353-8020",
publisher = "Elsevier BV",
number = "6",

}

TY - JOUR

T1 - Severity of depression and anxiety are predictors of response to antidepressant treatment in Parkinson's disease

AU - Moonen, A. J H

AU - Wijers, A.

AU - Leentjens, A. F G

AU - Christine, C. W.

AU - Factor, S. A.

AU - Juncos, J.

AU - Lyness, J. M.

AU - Marsh, L.

AU - Panisset, M.

AU - Pfeiffer, Ronald

AU - Rottenberg, D.

AU - Serrano Ramos, C.

AU - Shulman, L.

AU - Singer, C.

AU - Slevin, J.

AU - McDonald, W.

AU - Auinger, P.

AU - Richard, I. H.

PY - 2014

Y1 - 2014

N2 - Background: Antidepressants have appeared to be more effective than placebo treatment in treating depressive syndromes in patients with Parkinson's disease (PD). Objective: To identify factors that predict improvement in depressive symptoms during antidepressant treatment in depressed PD patients. Methods: A secondary analysis was performed on the dataset of the Randomized Placebo-controlled Study of Antidepressants in PD (SAD-PD), in which 76 patients received active treatment with either paroxetine or venlafaxine extended release (XR), and 39 patients received placebo treatment. Backward stepwise regression analyses were conducted with change in 24-item Hamilton Depression Rating Scale (HAMD-24) score between assessments at baseline and week 12 as the main outcome measure, and sex, age, baseline HAMD-24 score, Unified Parkinson's Disease Rating Scale section III (UPDRS-III) score, Mini-Mental State Examination (MMSE), and the Clinical Anxiety Scale (CAS) as independent variables. Results: In both the active treatment and placebo groups, higher baseline HAMD-24 score and lower UPDRS-III score were associated with greater reduction in HAMD-24 score. Higher anxiety scores predicted less response in the active treatment group. Higher MMSE scores predicted greater response only in the placebo-treated group. Sex and age were no predictors of response. Conclusions: Higher pre-treatment depression scores and lower pre-treatment anxiety scores are the two most important predictors for improvement during antidepressant treatment in depressed PD patients, which is in line with those found in treatment studies of depressed non-PD patients. Furthermore, our results indicate the requirement for different or more intensive treatment for depressed PD patients with more severe anxiety symptoms.

AB - Background: Antidepressants have appeared to be more effective than placebo treatment in treating depressive syndromes in patients with Parkinson's disease (PD). Objective: To identify factors that predict improvement in depressive symptoms during antidepressant treatment in depressed PD patients. Methods: A secondary analysis was performed on the dataset of the Randomized Placebo-controlled Study of Antidepressants in PD (SAD-PD), in which 76 patients received active treatment with either paroxetine or venlafaxine extended release (XR), and 39 patients received placebo treatment. Backward stepwise regression analyses were conducted with change in 24-item Hamilton Depression Rating Scale (HAMD-24) score between assessments at baseline and week 12 as the main outcome measure, and sex, age, baseline HAMD-24 score, Unified Parkinson's Disease Rating Scale section III (UPDRS-III) score, Mini-Mental State Examination (MMSE), and the Clinical Anxiety Scale (CAS) as independent variables. Results: In both the active treatment and placebo groups, higher baseline HAMD-24 score and lower UPDRS-III score were associated with greater reduction in HAMD-24 score. Higher anxiety scores predicted less response in the active treatment group. Higher MMSE scores predicted greater response only in the placebo-treated group. Sex and age were no predictors of response. Conclusions: Higher pre-treatment depression scores and lower pre-treatment anxiety scores are the two most important predictors for improvement during antidepressant treatment in depressed PD patients, which is in line with those found in treatment studies of depressed non-PD patients. Furthermore, our results indicate the requirement for different or more intensive treatment for depressed PD patients with more severe anxiety symptoms.

KW - Clinical trials randomized controlled

KW - Depression

KW - Parkinson's disease

KW - Paroxetine

KW - Venlafaxine

UR - http://www.scopus.com/inward/record.url?scp=84900012852&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84900012852&partnerID=8YFLogxK

U2 - 10.1016/j.parkreldis.2014.02.025

DO - 10.1016/j.parkreldis.2014.02.025

M3 - Article

VL - 20

SP - 644

EP - 646

JO - Parkinsonism and Related Disorders

JF - Parkinsonism and Related Disorders

SN - 1353-8020

IS - 6

ER -